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Context and Objective: 11-hydroxysteroid dehydrogenase type 1 (11HSD1) catalyses regener-
ation of cortisol in liver, adipose tissue, and skeletal muscle, making a substantial contribution to
circulating cortisol as demonstrated in humans by combining stable isotope tracer infusion with
arteriovenous sampling. In the brain, 11HSD1 is a potential therapeutic target implicated in
age-associated cognitive dysfunction.We aimed to quantify brain 11HSD1 activity, both to assess
its contribution to systemic cortisol/cortisone turnover and to develop a tool for measuring
11HSD1 in dementia and following administration of 11HSD1 inhibitors.
Design, Setting, and Participants:With ethical approval and informed consent, 8 healthy men
aged 38.1 years (sd 16.5) underwent an ECG-gated phase-contrast magnetic resonance scan to
quantify internal jugular vein blood flow and were infused with 1,2 [2H]2-cortisone and
9,11,12,12 [2H]4-cortisol for 3 h before samples were obtained from the internal jugular vein
and an arterialized hand vein. Steroids were quantified by liquid chromatography-tandem
mass spectrometry.
MainOutcomeMeasures and Results: Steady state tracer enrichmentswere achieved and systemic
indices of cortisol/cortisone interconversion were consistent with previous studies in healthy men.
However, there was no measurable release or production of cortisol, 9,12,12 [2H]3-cortisol or
cortisone into the internal jugular vein.
Conclusions:Although cerebral 11HSD1 reductase activitymaybegreater in cognitively impaired
patients, in healthy men any contribution of 11HSD1 in the brain to systemic cortisol/cortisone
turnover is negligible. The influence of 11HSD1 in the brain is likely confined to subregions,
notably the hippocampus. Alternative approaches are required to quantify pharmacodynamics
effects of 11HSD1 inhibitors in the human brain. (J Clin Endocrinol Metab 100: 483–489, 2015)
The 11-hydroxysteroid dehydrogenases (11HSDs)are intracellular enzymes that catalyze interconver-
sion of inactive cortisone and active cortisol; 11HSD
type 1 is a predominant reductase, regenerating cortisol
from cortisone, while 11HSD type 2 is an exclusive de-
hydrogenase, inactivating cortisol to cortisone. An exten-
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sive literature documents the role of 11HSDs in regulat-
ing intracellular glucocorticoid concentrations and hence
modulating tissue-specific activation of corticosteroid re-
ceptors (reviewed in 1, 2). 11HSD1 amplifies glucocor-
ticoid action in the liver, adipose tissue, inflammatory
cells, and vasculature, providing a therapeutic target for
inhibition in type 2 diabetes. 11HSD2 limits cortisol ac-
tion, and thereby facilitates aldosterone action in thedistal
nephron and a few other sites, explaining the mineralo-
corticoid excess state which ensues when 11HSD2 is in-
hibited by licorice.
Both 11HSD isozymes also contribute to systemic
turnover of cortisol. Activity of the two isozymes has been
quantified in humans using stable isotope (deuterated)
glucocorticoid tracers (Figure 1). Production of cortisone
can be measured by the rate of dilution of 1,2-[2H]2-cor-
tisone (d2-cortisone) by cortisone, and is inhibited by
licorice (3). A more complex tracer is used to measure
regeneration of cortisol by 11HSD1: 9,11,12,12-[2H]4-
cortisol (d4-cortisol) is infused and production of cortisol
is measured by the rate of dilution of d4-cortisol by cor-
tisol (an index of net cortisol production from all sources,
including the adrenal gland) and by 9,12,12-[2H]3-corti-
sol (d3-cortisol, a specificmeasure of cortisol regeneration
by 11HSD1) (4). Using these tracers in combination
with selective venous catheterization andmeasurement of
blood flow has allowed quantification in humans of cor-
tisol-cortisone interconversion in splanchnic (3, 5, 6), sub-
cutaneous adipose (3, 7), and skeletal muscle (3) circula-
tions, and exclusion of significant 11HSD activity in the
myocardium (8). These studies reveal rapid shuttling be-
tween cortisol and cortisone such that in healthy men at
rest, remarkably, the magnitude of extra-adrenal regen-
eration of cortisol by 11HSD1 is greater than the mag-
nitude of adrenal cortisol secretion. They also suggest,
surprisingly, that 11HSD1 may catalyze both reductase
and dehydrogenase activity in vivo, resulting in “recy-
cling”between cortisol and cortisone (detectedbydilution
of d2-cortisone by cortisone and by simultaneous dilution
ofd4-cortisolbyd3-cortisol) even in tissueswhere11HSD2
is not expressed (3).
11HSDs may also play key roles in the brain (9).
11HSD2 is expressed in the developing, but not the adult
brain (10). 11HSD1 is expressedmorewidely in the adult
brain, and notably in the prefrontal cortex, hippocampus,
and cerebellum, a distribution confirmed in humans (11).
Increased local regeneration of cortisol by 11HSD1may
cause glucocorticoid-dependent neurotoxicity and hence
contribute to cognitive aging and dementia, while inhibi-
tionof 11HSD1hasbeenproposed as a therapeutic strat-
egy to treat age- and dementia-associated cognitive dys-
function. In mice, 11HSD1 levels in the hippocampus
and parietal cortex rise with age and correlate with im-
paired cognitive performance, while transgenic overex-
pression of 11HSD1 in the forebrain accelerates age-
associated cognitive decline (12). Conversely, 11HSD1
knockout mice are protected from age-related learning
impairment (13, 14). Moreover, selective 11HSD1 in-
hibitors, after either systemic or intracerebroventricular
administration, improve cognitive function in aged mice
(14). Indeed in humans, the nonselective 11HSD inhib-
itor carbenoxolone improved cognitive performance in
healthy elderly and diabetic men (11). However, a recent
phase II clinical trial of a selective 11HSD1 inhibitor,
ABT384, in patients with mild-to-moderate Alzheimer’s
disease was halted prematurely because of lack of efficacy
(15). It is uncertain whether this reflected selection of pa-
tients whose cognitive dysfunction is no longer responsive
to reducing cortisol action, or inadequate inhibition of brain
11HSD1 by ABT384.
Against this background, quantification of brain
11HSD1 activity in vivo in humans would be highly
desirable. Here, we aimed: (i) to determine whether, as a
major organ by mass, brain 11HSD1 contributes to cor-
tisol/cortisone turnover in vivo; (ii) to establish whether
11HSD1, as the only 11HSD isozyme expressed in an
Figure 1. Stable isotope tracers for measuring cortisol-cortisone
interconversion by 11-HSDs. 11-HSD2 is a unidirectional enzyme
catalyzing the dehydrogenase conversion of cortisol to cortisone.
11-HSD1 is a potentially reversible enzyme catalyzing
interconversion of cortisol and cortisone, predominantly in the
reductase (cortisone to cortisol) direction. The shaded boxes on left
and right represent the circulating pools of cortisol and cortisone,
respectively. Production of cortisone can be measured by infusing a
tracer, d2-cortisone, into the cortisone pool and measuring its dilution
by cortisone. Similarly, production of cortisol can be measured by
infusing a tracer, d4-cortisol, into the cortisol pool. When d4-cortisol is
metabolized by 11-HSD2, the deuterium in the 11 position is
removed, producing d3-cortisone; when this d3-cortisone is converted
back to cortisol by 11-HSD1 it is highly unlikely that a deuterium
rather than a proton will be reincorporated, so that d3-cortisol is
produced. Dilution of d4-cortisol with d3-cortisol therefore indicates
11-HSD1 reductase activity.
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adult brain (11), catalyzes only regeneration of cortisol or
also recycling between cortisol and cortisone; (iii) to pro-
vide a toolwithwhich to quantify changes in human brain
11HSD1 activity with dementia, and to use as a phar-
macodynamics biomarker to quantify enzyme inhibition
during clinical development of selective 11HSD1 inhib-
itors for treating dementia. We therefore extended our
previous studies using arteriovenous sampling with stable
isotope tracer infusions in vivo to quantify 11HSD ac-
tivities in the human brain.
Materials and Methods
Participants
Participants were recruited through advertisements in the lo-
cal press and around the University campus. Participants were
healthy male volunteers between 18 and 70 years old. Exclusion
criteria were glucocorticoid medication (by any route of admin-
istration) within the past 3 months; diabetes mellitus, cerebro-
vascular disease or other significant chronic illness; history of
recent heavy alcohol or illegal drug use; current use of any im-
munosuppressivemedication; abnormal screening liver, thyroid,
renal or coagulation function (ie, INR 1.5 or platelets 50
109/L) or abnormal full blood count or random blood glucose;
research participant in the previous 3 months; any contraindi-
cation tomagnetic resonance (MR) imaging.The study complied
with the Declaration of Helsinki; ethical approval was obtained
from the local Research Ethics Committee (Scotland A REC,
reference 12/SS/0079) and all participants gavewritten informed
consent.
Reagents
Reagentswere obtained fromSigma, Steraloids, orVWR. 1,2
[2H]2-cortisone (d2-cortisone) and 9,11,12,12 [
2H]4-cortisol
(d4-cortisol) were from Cambridge Isotope Laboratories. Sol-
vents were high-performance liquid chromatography (HPLC)
grade from Fisher Scientific.
Clinical protocol
Screening testswereperformedwithin the2weeksprior to the
procedure.On thedayof the study, subjects attended theClinical
Research Facility at around 0830 h. They were allowed to eat a
light breakfast at home, but were only allowed water after their
arrival at the research facility. They first underwent an ECG-
gated phase contrast MR neck scan, which lasted 20–30 min.
After this, a cannula was inserted into the left antecubital fossa
and blood was taken to measure baseline endogenous steroids
and their background isotopomers. At t  5 min a 0.7 mg
loading bolus of d4-cortisol was given intravenously (IV), fol-
lowedby an infusion at 0.35mg/h (15.94nmol/min) at t0min.
Acannulawas inserted into a vein in thedorsumof the right hand
in a retrograde direction andwhen required the handwas placed
in a hot box at 60°C to arterialize the blood. Arterialization of
the blood was accepted if the oxygen saturation was 98%.
A jugular bulb cannula was inserted in the dominant internal
jugular vein (assessed by MR venography) under ultrasound
guidance. Placement was checked using a plain lateral C-spine
x-ray: the tip of the catheterwas visualized to ensure itwas above
the second cervical vertebra (16). The oxygen saturation of the
blood was checked to ensure it was 85%.
At t  145 min a 76.0 g bolus of d2-cortisone was admin-
istered IV, followed by an infusion at 105.3g/h (4.88 nmol/min).
From t 180min four sets of simultaneous blood samples were
taken from the arterialized and jugular bulb cannulae at 10 min
intervals (t 180, 190, 200, and 210min) into Lithium heparin
and plasma separated and stored at 80°C until analysis.
Magnetic resonance scanning
The MR imaging was performed with participants in the su-
pine position on a 1.5 Tesla MR imaging unit (Signa HDxt, GE
Healthcare) at the Brain Research Imaging Centre (www.bric.
ed.ac.uk).An eight-channel neurovascular array coilwas used.A
noncontrast MR angiogram of the carotids from the level of the
exterior auditory meatus down to the angle of the mandible was
performed, followed by an MR venogram over the same area
with a saturation band over the inferior aspect of the slices. The
MR venogram was used to select the level for the ECG-gated
phase-contrastMRscanbymeasuring aquarter of thewaydown
from the jugular bulb to where the facial vein enters the internal
jugular vein; axial images were taken perpendicular to the table.
This level was chosen to ensure blood flow was measured in the
vessel before any of the tributaries entered. The facial vein was
the first, and to avoidmeasuring flowdynamics in the bulb itself,
it may not be representative of the rest of the vessel, as there may
be some pooling of blood where it first enters the bulb. Sixteen
phase and magnitude images were taken at this level over one
cardiac cycle. The flip angle was 25°, bandwidth 15.63 kHz,
echo time (TE) 6 ms, repetition time (TR) 25 ms, and encoding
velocity (Venc) 100 cm/s. Data were checked at the point of ac-
quisition for any aliasing artifact. The field of view (FOV) was
25.6 cm  25.6 cm and slice thickness of 5 mm. These images
took approximately 8 min to acquire per patient, depending on
the heart rate.
The image analysis software Medis Q flow (Medis medical
imaging systems) was used to calculate jugular venous blood
flow inmL/min on the sidewhichwas cannulated. The outline of
the internal jugular vein was traced on each of the magnitude
images from the cardiac cycle and blood flow calculated using
data from the corresponding phase images. For completeness,
the blood flow for the opposite internal jugular vein and both
common carotid arteries were also measured.
Laboratory analysis
Steroids (cortisol, d4-cortisol, 9,12,12 [2H]3-cortisol (d3-
cortisol), cortisone and d2-cortisone) were quantified using
liquid chromatography-tandem mass spectrometry (LC-MS).
An internal standard solution [0.5 microg epicortisol (Steraloids),
0.25microg2,2,4,6,6,9,12,12[2H]8-cortisone(d8-cortisone,Santa
Cruz Biotechnology), and 0.25 microg 2,2,4,6,6,17A,21,21
[2H]8-corticosterone (d8-corticosterone, Cambridge Isotope
Laboratories) with 9 L methanol] was added to 1.5 mL of
plasma, before 15mLof chloroformwas added for extraction of
the steroids. The organic phase was then reduced to dryness
under oxygen free nitrogen at 60°C before being reconstituted in
the mobile phase [acetonitrile: water (35:65) with 0.1% formic
acid]. Samples were injected on to a Sunfire C18 column (150
mm 4.6mm 5m),with a column temperature of 10°C and
a mobile phase flow rate of 1.5 mL/min using an Acquity Ultra
Performance Liquid Chromatograph (Waters) coupled to a
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Qtrap 5500 mass spectrometer (AB Sciex). Ionization was
achieved in the positive electrospray mode. The following tran-
sitions (precursor3product mass-to-charge ratios) used were as
follows: cortisol (3633121), d2-cortisol (3653121), d3-corti-
sol (3663121), d4-cortisol (3673121), cortisone (361377),
d3-cortisone (3643164), and d2-cortisone (3633165). Steroid
concentrations and tracer/tracee ratioswere calculated from cal-
ibration curves and corrected for background isotopomer en-
richments as described previously (17).
Data analysis and kinetic calculations
Whole-body rate of appearance (Ra) of cortisol, d3-cortisol,
and cortisone were calculated by dividing the rate of tracer in-
fusion by the relevant tracer/tracee ratio (d4-cortisol/cortisol,
d4-cortisol/d3-cortisol and d2-cortisone/cortisone, respectively)
(3, 4). Brain tissue production of cortisol was calculated using
data from arterial (A) and internal jugular vein (V) samples and
corrected for cerebral blood flow using Eq. (1). Brain tissue pro-
duction of d3-cortisol and cortisone were also calculated with
Eq. (1), substituting arterial concentrations of d3-cortisol or cor-
tisone and the relevant arterial and venous tracer:tracee ratios, as
appropriate (3).Net release or uptake of cortisol across the brain
was calculated using Eq. (2). Net release or uptake of d4-cortisol
or cortisone were also calculated with Eq. (2), substituting ar-
terial and venous concentrations of d4-cortisol and cortisone,
respectively.
Tissue cortisol production (Blood flow [cortisolA])
 d4-coristol: cortisolAd4-coristol: cortisolV(Blood flow [cortisolA]) (1)
Net cortisol release ([cortisolV][cortisolA])
 (Blood flow) (2)
Statistical analysis
There were no prior data for cortisol or cortisone production
or uptake across the brain onwhich to base a power calculation,
therefore we used previous data from a study on cortisol and
cortisone production in skeletal muscle in healthy men (3). We
calculated that in order to detect the same magnitude of differ-
ence from zero for net uptake or release across the brain of cor-
tisol, d3-cortisol or cortisone, with a similar variance to that in
skeletal muscle, would require sample sizes of 3, 5, and 7, re-
spectively (for alpha 0.05, power 80% in a two-tailed test). We
therefore considered a sample size of 8 to be reasonable.
Using SPSS, the student t-test was used to detect a difference
from zero in brain production of cortisol, d3-cortisol, and cor-
tisone. The small n in the study required the use of parametric
tests, despite being unable to fully check the assumptions (18).
However, on visual inspection there were no obvious outliers
and the data appeared to meet the assumptions of normality.
Results
Eight healthy men were recruited with a mean age of 38.1
years (sd 16.5) and mean BMI of 24.9 kg/m2 (sd 3.7). In 7
of the 8 subjects, the right internal jugularwas found to be
dominant or co-dominant on the MR scan and was used
for cannulation and measurement of blood flow. In one
subject, the left internal jugular vein (IJV) was dominant
and was cannulated instead. Mean blood flow in the se-
lected left internal jugular vein for all subjects was 481
mL/min (sd 232).
Endogenous cortisol and cortisone concentrations in
both arterialized and jugular venous samples reduced
from baseline to 180 min of infusion, when the first set of
arteriovenous samples were obtained, which is consistent
with diurnal variation (Figure 2, A and D). In both arte-
rialized and jugular venous samples, concentrations of
cortisol and cortisone and tracer/tracee ratioswere similar
at all four sampling time points between 180 and 210min
of infusion, consistentwith the steady state being achieved
(Figure 2).
Mean values in arterialized samples in the steady state
were used to calculate whole body rates of appearance of
cortisol, d3-cortisol, and cortisone (Table 1), all of which
were readily detectable, confirming technical success of
the tracer infusions. Mean steady state data from arteri-
alized and jugular venous samples were combined with
blood flow measurements to calculate net release (or up-
take) of cortisol and cortisone [Eq. (2)] and to estimate
cortisol, d3-cortisol, and cortisone production across the
brain [Eq. (1)] (Table 1). Surprisingly, d4-cortisol concen-
trations were higher in the jugular vein than arterialized
samples, so that there was a net release of d4-cortisol
across the brain in the steady state. No other indices of
brain steroid release/uptake or production were signifi-
cantly different from zero.
Discussion
We found no detectable interconversion of cortisol and
cortisone across the human brain in eight healthy male
volunteers, using deuterated glucocorticoid tracers and
arteriovenous sampling. Previous studies using this ap-
proach have detected interconversion of cortisol plus or
minus cortisone within liver, adipose tissue, and skeletal
muscle (3, 5–7). Systemic cortisol/cortisone turnover val-
ues were similar in the subjects reported here to those
observed in previous studies, so the approach was tech-
nically successful. The lack of statistically significant net
production or release of cortisol, d3-cortisol or cortisone
across the brain could not be attributed to variability in
blood flow, either methodological due to the magnetic
resonancemethod used, or biological due to asymmetry of
internal jugular blood flow. Since we did not observe ex-
pected gradients in relevant steroid concentrations from
arterialized to jugular venous blood, we sampled from the
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dominant jugular vein, and therefore from venous drain-
age of a substantial proportion of brain tissue. Any con-
tribution of 11HSD in the brain to whole body turnover
between cortisol and cortisone is, therefore, negligible. It
remains possible that, hadwe sampled fromdiscreet brain
subregions, 11HSD activity might have been measur-
able, but this remains a speculation. The consequences of
brain 11HSD1 activity are likely to be confined to the
subregions in which the enzyme is highly expressed (11).
In the absence of arteriovenous gradients in cortisol
or cortisone concentrations, we did find a net release of
d4-cortisol across the brain. It is unclear why there was
release of tracer from the brain but it
may indicateoverprimingandhigher
circulating d4-cortisol levels earlier
in the infusion, with resulting rer-
elease from the brain during steady
state.However, this speculation can-
not be tested in the absence of earlier
samples.
One previous study has evaluated
in vivo 11HSD1 activity in the
brain, by measuring peripheral ve-
nous plasma and cerebrospinal fluid
(CSF) steroid concentrations during
d4-cortisol infusion (19). Unfortu-
nately, data were presented for only
two subjects without administra-
tion of a potent 11HSD1 inhibitor.
Strangely, these subjects did not ap-
pear to reach steady state of tracer
enrichment after 4 h of infusion and
tracer/tracee ratios in plasma were
not adjusted for d4-cortisol infusion
to calculate the rate of appearance of
cortisol andd3-cortisol andestablish
if the results were comparable with
other published studies. CSF d3-
cortisol concentrations were shown
to be higher, relative to d4-cortisol,
than plasma d3-cortisol concentra-
tions, but only by comparing CSF
data with plasma obtained 60 min
earlier. This adjustment was applied
on the grounds of closer correlation
between plasma and CSF steroid
concentrations separated by 60 min
than those separated by shorter or
longer intervals, but again indicates
that steady state was not achieved in
CSF. The authors attributed the ap-
parent excess of d3-cortisol inCSF to
brain 11HSD1, partly on the basis
that it was abolished in a dose-dependent fashion by ad-
ministration of the 11HSD1 inhibitor ABT384. How-
ever,ABT384dramatically loweredplasmad3-cortisol con-
centrations, consistent with potent inhibition of systemic
11HSD1 activity. The associated fall in CSF d3-cortisol
concentrations, which fell below the limit of quantifica-
tion inmost samples, can be explained by the dramatic fall
in plasma d3-cortisol without invoking any contribution
of brain 11HSD1. Against this background, it has not
been established whether activity of 11HSD1 in the
brain is sufficient in magnitude to affect CSF cortisol
concentrations.
Figure 2. Arterialized and jugular venous steroid concentrations and tracer/tracee ratios during
steady state stable isotope tracer infusion. Data are mean  SEM for n  8. (A) Cortisol
concentration; (B) cortisone concentration; (C) d4-cortisol/cortisol ratio; (D) d4-cortisol/d3-cortisol
ratio; (E) d2-cortisone/cortisone ratio. Statistical comparisons were made for the kinetic
parameters derived from these “raw” data (Table 1).
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We took a different approach to measuring steroids in
jugular venous blood and calculating arteriovenous dif-
ferences during steady state tracer infusion.With themea-
surement of blood flow, this allows absolute quantifica-
tion of 11HSD activities for all tissue draining to the
cannulated internal jugular vein. 11HSD1 is known tobe
expressed in specific neuronal subregions of the human
brain: hippocampus (in particular the dentate gyrus and
the cornu ammonis), prefrontal cortex, and the area of
highest expression, the granule cell layer of the cerebellum
(11). The venous drainage of the human brain is complex
and appears to display considerable interindividual dif-
ferences. Cerebellar venous blood drains to the superior
and inferior cerebellar veins and usually ultimately into
the internal jugular veins. However, posture affects cere-
brovenous drainage such that in the supine position the
internal jugular veins drain around 95% of blood flow
from the intracerebral structures, while in the erect posi-
tion this can drop to as little as 25%, with the remainder
draining through the vertebral venous plexus (20). Our
subjects were reclining at an angle of 45° for the arterio-
venous sampling, but the measure of internal jugular vein
blood flow was performed supine within a magnetic res-
onance imaging (MRI) machine. It could be that during
blood sampling more of the cerebellar venous drainage
was to the vertebral venous system rather than to the in-
ternal jugular veins, and that the brain 11HSD1 was
underestimated as a result. Moreover, the forebrain sub-
regions where 11HSD1 is expressed represent a minor-
ity, by mass, of forebrain tissue and hence any contribu-
tion of these subregions to the plasma steroid pool may be
diluted by blood from elsewhere. More selective venous
cannulation might therefore detect 11HSD1 activity,
which was not measurable here, but this is unlikely to be
feasible in healthy volunteers.
As there were no previous data on brain release or up-
take of cortisol or cortisone, sample size was calculated
using data from a previous study on skeletal muscle (3).
With the current novel results from the brain in hand, we
have performed new power calculations which show that
to demonstrate that the observedmean differences are sta-
tistically significantly different from zero for Ra cortisol,
Ra d3-cortisol, and net Ra cortisone, we would need sam-
ple sizes of 40, 57, and 4006, respectively (for alpha 0.05,
power 90% in a two-tailed test). We do not consider it
justified to undertake invasive studies in this large number
of subjects in order to more precisely quantify any small
amount of cortisol production in the brain, having shown
its mean magnitude to be negligible relative to other
tissues.
If 11HSD activity in the brain had been detectable
with the approach used here, this could have provided a
useful pharmacodynamic tool to quantify brain enzyme
inhibition by selective 11HSD1 inhibitors in develop-
ment for treatment of dementia (14, 19). As things stand,
neither this approach nor the CSF approach attempted by
Katz et al (19) appear well-suited for this purpose in
healthy volunteers. Given that 11HSD1 expression in-
creases with age in mice and is predictive of cognitive de-
cline (12), it remains possible that arteriovenous sampling
could be used to detect cortisol regeneration by 11HSD1
in the brains of patients with dementia or with risk factors
for cognitive decline (eg, diabetes, older age).
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